A detailed history of New York State Common Retirement Fund transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 16,229 shares of ORIC stock, worth $133,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,229
Previous 16,229 -0.0%
Holding current value
$133,240
Previous $115,000 44.35%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$6.63 - $12.93 $188,855 - $368,311
-28,485 Reduced 63.7%
16,229 $115,000
Q1 2024

May 07, 2024

BUY
$8.04 - $16.03 $282,557 - $563,358
35,144 Added 367.23%
44,714 $615,000
Q4 2023

Feb 01, 2024

SELL
$5.41 - $9.43 $33,168 - $57,815
-6,131 Reduced 39.05%
9,570 $88,000
Q3 2023

Nov 07, 2023

BUY
$6.05 - $9.28 $2,426 - $3,721
401 Added 2.62%
15,701 $95,000
Q2 2023

Aug 07, 2023

BUY
$4.95 - $8.4 $75,735 - $128,520
15,300 New
15,300 $119,000
Q2 2022

Aug 04, 2022

SELL
$2.7 - $7.07 $52,110 - $136,451
-19,300 Reduced 98.55%
283 $1,000
Q1 2022

May 05, 2022

BUY
$4.54 - $16.1 $118 - $418
26 Added 0.13%
19,583 $105,000
Q4 2021

Feb 02, 2022

SELL
$12.01 - $20.3 $49,781 - $84,143
-4,145 Reduced 17.49%
19,557 $287,000
Q3 2021

Nov 02, 2021

SELL
$15.9 - $25.22 $57,001 - $90,413
-3,585 Reduced 13.14%
23,702 $496,000
Q2 2021

Aug 02, 2021

BUY
$17.37 - $25.34 $100,520 - $146,642
5,787 Added 26.92%
27,287 $483,000
Q1 2021

May 11, 2021

BUY
$23.67 - $36.85 $73,377 - $114,235
3,100 Added 16.85%
21,500 $527,000
Q4 2020

Feb 08, 2021

BUY
$20.32 - $39.8 $211,328 - $413,919
10,400 Added 130.0%
18,400 $623,000
Q2 2020

Aug 07, 2020

BUY
$25.68 - $38.12 $205,440 - $304,960
8,000 New
8,000 $270,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $325M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.